The post-authorization safety cohort observational study (PASCO I) was carried out in four European countries and included 1,634 anaemic patients with chronic kidney disease receiving haemodialysis and who were treated with Retacrit/Silapo administered intravenously for up to one year. The primary objective of PASCO I was to determine the incidence of adverse events of special interest (AESI) and lack of efficacy events in patients being treated with Retacrit/Silapo for renal anaemia.

AESI frequencies were thromboembolic events 6.4% (n = 105), cerebrovascular events 1.8% (n = 30) and clotting of artificial kidney 9.8% (n = 160). There were no reports of pure red cell aplasia, neutralizing antibodies, anaphalactoid reactions or angioedema. Lack of efficacy occurred in 2.4% of subjects (n = 39), although 27 of these cases were attributed to infection or inflammation.

The results of the study, which were conducted as part of the risk management plan (RMP) post-approval commitment to the European Medicines Agency (EMA), were presented at the National Kidney Foundation’s 2014 Spring Clinical Meetings. The data showed that the safety pattern for Retacrit/Silapo was comparable with known data for other existing epoetin products.

Retacrit is marketed in Europe by Hospira and Silapo is marketed in Germany by Cell Pharm, a subsidiary of STADA Arzneimittel. Hospira and STADA Arzneimittel are currently conducting an additional post-authorization safety cohort observational study (PASCO II) intended to further the safety profile of Retacrit/Silapo given subcutaneously over a period of three years in 6,700 European patients being treated for anaemia associated with renal disease. As with PASCO I, this study is also being conducted as part of an RMP commitment to EMA for further pharmacovigilance surveillance.

Conflict of interest
Several of the authors of the research paper [1] reported conflicts of interest, including having received honoraria, consultancy fees or principal investigator fees from pharmaceutical companies or being employees of STADA Arzneimittel or Hospira. For more details see [1].

Related articles

Sandoz starts phase III US trial for biosimilar epoetin alfa

Amgen, Hospira and Sandoz set to dominate US biosimilars market

Reference
1. Dellanna F, Fluck R, Lonnemann G, Wild CA, Iwanowitsch A, Meissner R, et al. Results from a safety study of patients with renal anemia receiving the biosimilar Retacrit™ / Silapo™ (epoetin zeta): the PASCO I study. Poster 64. National Kidney Foundation 2014 Spring Clinical Meetings; 22-26 April 2014; Las Vegas, USA.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.